北京昭衍新药研究中心股份有限公司（“昭衍新药”，06127）于2026年3月4日发布截至2026年2月28日的股份变动月报表。报告期内，公司无新增发行、购回及注销股份，整体股本维持稳定。
公司现有H股及A股两类股份。月末H股已发行股本为118,995,206股，与上月持平；A股已发行股本为630,353,014股（其中627,179,094股为流通股，3,173,920股为库存股），与上月保持一致。公司确认符合香港联交所相关上市规则，对外已发行股份数量未发生任何变化。
月报显示，期间无股份期权、权证及可换股票据等相关事宜。公司也未进行任何股份购回与注销，股本情况较上月保持不变。公司表示，其董事会正式授权并遵守香港联交所《上市规则》及相关法律法规。公告由联席公司秘书高大鹏签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.